Top AI executives, including Sam Altman of OpenAI, Dario Amodei of Anthropic, and Demis Hassabis of Google’s DeepMind, are urging Congress to implement safeguards against biological threats linked to artificial intelligence. They have joined security experts in a letter that emphasizes the need for regulations on the ordering of synthetic DNA and RNA, which are critical in biotech advancements like vaccine development. This initiative highlights an increasing concern among industry leaders about the potential misuse of AI technologies in biotechnology, further pressuring lawmakers to act.

OpenAI: OpenAI develops and deploys advanced artificial intelligence systems for research and practical applications. Its CEO Sam Altman is a signatory to a letter urging Congress to mandate safeguards against the use of AI in creating biological threats through synthetic DNA and RNA ordering.
Anthropic: Anthropic builds AI models with an emphasis on safety and reliability for various applications. Its CEO Dario Amodei signed the letter to Congress calling for protections against AI-enabled biological risks in biotechnology processes.
Sam Altman: Sam Altman leads OpenAI as its chief executive officer. He is among the top AI executives signing the letter to Congress that addresses biological threats from AI technology.
Dario Amodei: Dario Amodei serves as CEO of Anthropic. He signed the letter urging Congress to require safeguards when companies order synthetic DNA and RNA to counter AI-related biological risks.
Demis Hassabis: Demis Hassabis heads Google DeepMind as its CEO. He is a signatory to the letter from AI leaders pressing lawmakers to protect against biological threats posed by the technology.
Google DeepMind: Google DeepMind conducts AI research under Google to advance capabilities across scientific and technological domains. Demis Hassabis, its leader, joined other AI executives as a signatory to advocate for congressional safeguards on synthetic genetic material orders.

Policy: The letter focuses on requiring safeguards for companies ordering synthetic DNA and RNA as a step to mitigate biological weapon risks.
Regulation: AI executives and security experts are jointly urging Congress to address potential misuse of artificial intelligence in biotechnology.